🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

Recruitingn/aAges 18 Years - 80 YearsAllShanghai Pulmonary Hospital, Shanghai, China
NCT06760273 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The ERASE II study is a prospective follow-up study designed to assess the long-term impact of successful eradication of Pseudomonas aeruginosa (PA) in patients with bronchiectasis. Building on the findings of the initial ERASE study, which evaluated the efficacy and safety of Tobramycin Inhalation Solution, ERASE II aims to determine whether successful PA eradication influences patient prognosis over an extended period. The study will involve a total observation period of 36 months, consisting of the initial 9 months of the ERASE study followed by an additional 27 months of comprehensive follow-up. Key outcomes to be assessed include patients' quality of life, lung function, frequency of pulmonary exacerbations, frequency of hospitalization, and overall treatment costs. Additionally, the study will examine the timing and incidence of any potential reinfections with Pseudomonas aerugino

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * all patients who participate the ERSE study * write the informed consent form. Exclusion Criteria: * patients who were lost of follow up in the ERASE study * ineligible for inclusion at the discretion of the researcher for other reasons.
💊

What it tests

  • No Intervention: Observational Cohort
📍

Where

58 sites
Anhui Chest Hospital
Hefei, China
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
The Third Affiliated Hospital of Chongqing Medical University
Chongqing, China
Fujian Provincial Hospital
Fuzhou, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China

…and 50 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy